1. Aspirin-triggered resolvin d1 reduces proliferation and the neutrophil to lymphocyte ratio in a mutant kras-driven lung adenocarcinoma model.
- Author
-
Vannitamby A., Saad M.I., Aloe C., Wang H., Kumar B., Vlahos R., Selemidis S., Irving L., Steinfort D., Jenkins B.J., Bozinovski S., Vannitamby A., Saad M.I., Aloe C., Wang H., Kumar B., Vlahos R., Selemidis S., Irving L., Steinfort D., Jenkins B.J., and Bozinovski S.
- Abstract
Tumour-associated neutrophils (TANs) can support tumour growth by suppressing cyto-toxic lymphocytes. AT-RvD1 is an eicosanoid that can antagonise neutrophil trafficking instigated by ALX/FPR2 ligands such as serum amyloid A (SAA). We aimed to establish whether SAA and ALOX5 expression associates with TANs and investigate the immunomodulatory actions of AT-RvD1 in vivo. MPO-positive neutrophils were quantified in tumour blocks from lung adenocarcinoma (n = 48) and control tissue (n = 20) by IHC. Tumour expression of SAA and ALOX5 were analysed by RTqPCR and an oncogenic KrasG12D lung adenocarcinoma mouse model was used to investigate the in vivo efficacy of AT-RvD1 treatment. ALOX5 expression was markedly reduced in lung adenocarcinoma tumours. The SAA/ALOX5 ratio strongly correlated with TANs and was significantly increased in tumours harbouring an oncogenic KRAS mutation. AT-RvD1 treatment reduced tumour growth in KrasG12D mice, which was accompanied by suppressed cellular proliferation within parenchymal lesions. In addition, AT-RvD1 significantly reduced the neutrophil to lymphocyte ratio (NLR), an established prognostic marker of poor survival in adenocarcinoma. This study identifies a novel molecular signature whereby elevated levels of SAA relative to ALOX5 favour accumulation of TANs. Furthermore, the ALOX5/5-LO enzymatic product, AT-RvD1, markedly reduced the NLR and suppressed tumour growth in KrasG12D mice.Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
- Published
- 2021